Barclays Maintains an 'Overweight' on Camelot Information Systems (CIS); Q1 Trends Mostly In-line
Tweet
Share
E-mailGet Alerts CIS Hot Sheet
Price: $2.03 --0%
Rating Summary:
0 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
0 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Camelot Information Systems (NYSE: CIS) price target of $6.00.
Analyst, Darrin D. Peller, said, "As CIS continued positioning itself to drive further revenue turnaround in its FIS business line, adjusted cost of revenues and sales/marketing expense increased sequentially as a percent of revenues, as anticipated. Excluding a change in goodwill accounting for a prior acquisition and a tax refund, 1Q adjusted EPS would likely have been slightly better than expectations."
Raising FY12 EPS Estimate from $0.36 to $0.40 (vs. consensus of $0.34). Barclays maintains FY13 at $0.60.
For an analyst ratings summary and ratings history on Camelot Information Systems click here. For more ratings news on Camelot Information Systems click here.
Shares of Camelot Information Systems closed at $2.41 yesterday.
Analyst, Darrin D. Peller, said, "As CIS continued positioning itself to drive further revenue turnaround in its FIS business line, adjusted cost of revenues and sales/marketing expense increased sequentially as a percent of revenues, as anticipated. Excluding a change in goodwill accounting for a prior acquisition and a tax refund, 1Q adjusted EPS would likely have been slightly better than expectations."
Raising FY12 EPS Estimate from $0.36 to $0.40 (vs. consensus of $0.34). Barclays maintains FY13 at $0.60.
For an analyst ratings summary and ratings history on Camelot Information Systems click here. For more ratings news on Camelot Information Systems click here.
Shares of Camelot Information Systems closed at $2.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
